Information Provided By:
Fly News Breaks for August 13, 2019
CHRS
Aug 13, 2019 | 05:05 EDT
Mizuho analyst Salim Syed started Coherus Biosciences with a Buy rating and $43 price target. The analyst views Coherus as a pure-play biosimilar company and his Udenyca peak sales estimate is $100M above consensus. He believes Udenyca alone is worth $30 per share.
News For CHRS From the Last 2 Days
There are no results for your query CHRS